Bioxytran (BIXT) Payables (2010 - 2026)
Bioxytran (BIXT) posted Payables of $1.5 million for Q1 2026, up 23.07% sequentially from $1.3 million in Q4 2025, and up 13.32% YoY from $1.4 million in Q1 2025.
Bioxytran (BIXT) Payables (2010 - 2026) Analysis & Trends
Bioxytran has reported Payables for 17 years, with the latest figure at $1.5 million in Q1 2026.
- Quarterly Payables rose 13.32% year-over-year to $1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (up 13.32% YoY) and the FY2025 annual result came in at $1.3 million, up 284.05% from the prior year.
- Payables rose to $1.5 million in Q1 2026 per BIXT's latest filing, from $1.3 million in the prior quarter.
- Over five years, Payables peaked at $4.2 million in Q2 2022 and troughed at $239014.0 in Q3 2024.
- A 5-year average of $1.7 million and a median of $1.4 million in 2025 frame the typical range for Payables.
- The sharpest annual moves came in 2022 and 2024: Payables surged 325.7% in 2022, then sank 89.39% in 2024.
- Over 5 years, Payables stood at $2.9 million in 2022, then fell by 24.54% to $2.2 million in 2023, then tumbled by 85.19% to $326258.0 in 2024, then soared by 284.05% to $1.3 million in 2025, then grew by 23.07% to $1.5 million in 2026.
- According to Business Quant data, Payables over the past three periods registered $1.5 million, $1.3 million, and $372457.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 108.02 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 428.93 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 35.57 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 622.65 Mn |
| 10 | Bioxytran | 2.47 Mn | 2.22 Mn | - | 2.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.54 Mn |
| Dec 31, 2025 | 1.25 Mn |
| Sep 30, 2025 | 372,457.00 |
| Jun 30, 2025 | 706,950.00 |
| Mar 31, 2025 | 1.36 Mn |
| Dec 31, 2024 | 326,258.00 |
| Sep 30, 2024 | 239,014.00 |
| Jun 30, 2024 | 835,252.00 |
| Mar 31, 2024 | 959,091.00 |
| Dec 31, 2023 | 2.20 Mn |
| Sep 30, 2023 | 2.25 Mn |
| Jun 30, 2023 | 2.56 Mn |
| Mar 31, 2023 | 3.27 Mn |
| Dec 31, 2022 | 2.92 Mn |
| Sep 30, 2022 | 2.50 Mn |
| Jun 30, 2022 | 4.15 Mn |
| Mar 31, 2022 | 1.31 Mn |
| Dec 31, 2021 | 2.75 Mn |
| Sep 30, 2021 | 587,044.00 |
| Jun 30, 2021 | 1.21 Mn |